Nationally Notifiable Infectious Diseases and Conditions, United States: Annual Tables

TABLE 7. Reported cases of notifiable diseases and rates per 100,000 population, by ethnicity*, excluding U.S. territories - - United States, 2016
Disease Hispanic Non-Hispanic Ethnicity not stated Total
No. Rate No. Rate No. No.
Anthrax
Arboviral diseases
Chikungunya virus disease 60 0.10 132 0.05 55 247
Eastern equine encephalitis virus disease
Neuroinvasive S S S S S 7
Non-neuroinvasive
Jamestown Canyon virus disease
Neuroinvasive S S S S S 7
Non-neuroinvasive S S S S S 8
La Crosse virus disease
Neuroinvasive 1 0.00 20 0.01 10 31
Non-neuroinvasive S S S S S 4
Powassan virus disease
Neuroinvasive S S S S S 21
Non-neuroinvasive S S S S S 1
St. Louis encephalitis virus disease
Neuroinvasive S S S S S 7
Non-neuroinvasive S S S S S 1
West Nile virus disease
Neuroinvasive 160 0.28 841 0.32 307 1,308
Non-neuroinvasive 33 0.06 581 0.22 227 841
Western equine encephalitis virus disease
Neuroinvasive
Non-neuroinvasive
Babesiosis
Total 72 0.17 1,011 0.54 827 1,910
Confirmed 63 0.15 818 0.44 704 1,585
Probable 9 0.02 193 0.10 123 325
Botulism
Total 39 0.07 119 0.04 43 201
Foodborne 4 0.01 18 0.01 9 31
Infant  28 2.73 87 2.95 29 144
Other (wound & unspecified) 7 0.01 14 0.01 5 26
Brucellosis 69 0.12 43 0.02 15 127
Campylobacteriosis 7,367 12.82 33,388 12.57 19,365 60,120
Chancroid S S S S S 7
Chlamydia trachomatis infection 212,027 368.93 767,700 288.98 618,627 1,598,354
Cholera S S S S S 15
Coccidioidomycosis § 1,964 8.04 3,301 3.09 6,564 11,829
Cryptosporidiosis
Total 1,137 1.98 8,867 3.34 3,449 13,453
Confirmed 827 1.44 5,615 2.11 2,195 8,637
Probable 310 0.54 3,252 1.22 1,254 4,816
Cyclosporiasis 106 0.19 320 0.13 111 537
Dengue virus infections 
Dengue 200 0.35 498 0.19 205 903
Dengue-like illness 8 0.01 21 0.01 11 40
Severe dengue S S S S S 10
Diphtheria
Ehrlichiosis and Anaplasmosis
Anaplasma phagocytophilum infection 52 0.09 2,557 1.00 1,542 4,151
Ehrlichia chaffeensis infection 28 0.05 918 0.36 431 1,377
Ehrlichia ewingii infection S S S S S 22
Undetermined ehrlichiosis/anaplasmosis 2 0.00 126 0.05 72 200
Giardiasis 1,063 2.50 8,829 4.18 6,418 16,310
Gonorrhea 54,300 94.48 277,814 104.58 136,400 468,514
Haemophilus influenzae, invasive disease
All ages, all serotypes 289 0.50 3,118 1.17 1,488 4,895
Age <5 years **
Serotype b 1 0.02 19 0.13 10 30
Non-b serotype 12 0.23 107 0.72 40 159
Nontypeable 28 0.54 109 0.74 59 196
Unknown serotype 35 0.68 104 0.70 48 187
Hansen's disease 10 0.02 48 0.02 20 78
Hantavirus infection, non-hantavirus pulmonary syndrome S S S S S 6
Hantavirus pulmonary syndrome 4 0.01 23 0.01 4 31
Hemolytic uremic syndrome post-diarrheal 36 0.06 228 0.09 43 307
Hepatitis ††
A, acute 293 0.51 1,232 0.46 482 2,007
B, acute 194 0.34 2,272 0.86 752 3,218
B, perinatal infection §§ 19 0.32 13 32
C, acute 191 0.35 1,941 0.78 810 2,942
Human immunodeficiency virus diagnoses 8,076 14.05 26,699 10.05 34,775
Influenza-associated pediatric mortality ¶¶ 20 0.11 49 0.09 13 82
Invasive pneumococcal disease
All ages 1,119 3.04 10,584 5.19 5,923 17,626
Confirmed 1,119 3.04 10,570 5.18 5,914 17,603
Probable S S S S S 23
Age <5 years ** 182 0.46 666 0.30 294 1,142
Confirmed 182 5.08 663 5.36 292 1,137
Probable S S S S S 5
Legionellosis 397 0.69 4,506 1.70 1,238 6,141
Leptospirosis 7 0.02 52 0.03 19 78
Listeriosis 87 0.15 564 0.21 135 786
Lyme disease
Total 546 0.95 13,833 5.23 22,050 36,429
Confirmed 365 0.64 9,666 3.66 16,172 26,203
Probable 181 0.32 4,167 1.58 5,878 10,226
Malaria 59 0.10 1,492 0.56 404 1,955
Measles
Total 6 0.01 44 0.02 35 85
Indigenous 6 0.01 29 0.01 33 68
Imported S S S S S 17
Meningococcal disease
All serogroups 55 0.10 262 0.10 58 375
Serogroups ACWY 17 0.03 91 0.03 18 126
Serogroup B 6 0.01 67 0.03 13 86
Other serogroups S S S S S 21
Unknown serogroup 30 0.05 88 0.03 24 142
Mumps 596 1.04 4,685 1.76 1,088 6,369
Novel Influenza A virus infections S S S S S 23
Pertussis 2,396 4.17 10,358 3.90 5,218 17,972
Plague S S S S S 4
Poliomyelitis, paralytic
Poliovirus infection, nonparalytic
Psittacosis S S S S S 12
Q fever
Total 22 0.04 88 0.03 54 164
Acute 20 0.03 73 0.03 39 132
Chronic 2 0.00 15 0.01 15 32
Rabies
Human
Rubella S S S S S 1
Rubella, congenital syndrome  S S S S S 2
Salmonellosis 7,406 12.89 33,064 12.45 13,380 53,850
Severe acute respiratory syndrome-associated coronavirus disease
Shiga toxin-producing Escherichia coli *** 1,274 2.22 4,984 1.88 1,911 8,169
Shigellosis 4,919 8.56 11,539 4.34 4,639 21,097
Smallpox
Spotted fever rickettsiosis
Total 108 0.19 2,887 1.09 1,274 4,269
Confirmed 4 0.01 93 0.04 57 154
Probable 104 0.18 2,794 1.06 1,217 4,115
Streptococcal toxic shock syndrome 23 0.10 201 0.11 59 283
Syphilis
Total, all stages ††† 22,694 39.49 58,751 22.12 6,597 88,042
Congenital  187 18.24 407 13.82 34 628
Primary and secondary 6,193 10.78 19,791 7.45 1,830 27,814
Tetanus 4 0.01 20 0.01 10 34
Toxic shock syndrome (other than Streptococcal) 5 0.01 25 0.01 10 40
Trichinellosis 1 0.00 20 0.01 5 26
Tuberculosis 2,601 4.53 6,656 2.51 15 9,272
Tularemia 10 0.02 174 0.07 46 230
Typhoid fever 40 0.07 281 0.11 55 376
Vancomycin-intermediate Staphylococcus aureus 5 0.01 78 0.04 25 108
Vancomycin-resistant Staphylococcus aureus
Varicella morbidity 1,559 3.05 5,034 2.41 2,360 8,953
Varicella mortality U U U U U U
Vibriosis
Total 127 0.22 843 0.32 303 1,273
Confirmed 125 0.22 818 0.31 298 1,241
Probable 2 0.00 25 0.01 5 32
Viral hemorrhagic fevers
Crimean-Congo hemorrhagic fever virus
Ebola virus
Guanarito virus
Junin virus
Lassa virus
Lujo virus
Machupo virus
Marburg virus
Sabia virus
Yellow fever S S S S S 1
Zika virus
Zika virus disease, congenital †,§§§ 18 1.76 5 0.17 7 30
Zika virus disease, non-congenital 2,079 3.62 1,680 0.63 1,373 5,132
Zika virus infection, congenital †,§§§ 16 1.56 3 0.10 26 45
Zika virus infection, non-congenital 463 0.81 262 0.10 186 911
  • —: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
  • U: Unavailable — The data are unavailable.
  • S: Suppressed
  • * Conditions with <25 cases reported in the year were not broken down by ethnicity.
  • † The rate is calculated using population less than 1 year of age.
  • § Reportable in <25 states.
  • ¶ Total number of reported laboratory-positive dengue cases, including all confirmed cases [by anti-dengue virus (DENV) molecular diagnostic methods or seroconversion of anti-DENV IgM] and all probable cases (by a single, positive anti-DENV IgM).
  • ** The rate is calculated using population less than 5 years of age.
  • †† Chronic hepatitis B and C data are not included in NNDSS tables but reported case counts are included in the annual Summary of Viral Hepatitis, published online by CDC's Division of Viral Hepatitis, available at https://www.cdc.gov/hepatitis/statistics/2015surveillance/index.htm.
  • §§ The rate is calculated using population less than 2 years of age.
  • ¶¶ The rate is calculated using population less than 18 years of age.
  • *** Includes Escherichia coli O157:H7; shiga toxin-positive, serogroup non-O157; and shiga toxin positive, not serogrouped.
  • ††† Includes syphilis of all stages, including cases where stage of syphilis is not stated.
  • §§§ Data reported to ArboNET using the national surveillance case definition for congenital Zika virus disease or infection (CSTE Position Statement 16-ID-01). Additional data reported to the US Zika Pregnancy Registry for outcomes of pregnancies with laboratory evidence of possible Zika virus infection are available at https://www.cdc.gov/zika/reporting/pregnancy-outcomes.html. Cases reported to the US Zika Pregnancy Registry might not meet the national surveillance case definition for congenital Zika virus disease or infection.